8-aminoguanosine and deoxyguanosine-triphosphate

The toxicity of guanosine and deoxyguanosine in the presence or absence of the purine nucleoside phosphorylase inhibitor, 8-aminoguanosine, for malignant lymphoid cell lines and mitogen-stimulated peripheral blood lymphocytes has been studied. Deoxyguanosine inhibited the proliferation of lymphoid cells more strongly than guanosine. Addition of 100 microM 8-aminoguanosine neither enhanced nor diminished the toxicity of guanosine to the lymphoid cells. Only the toxicity of deoxyguanosine for the leukemic T cell line, MOLT 4, and the leukemic nonBnonT cell line, KM-3, was enhanced by the addition of 100 microM 8-aminoguanosine. These data suggest a possible role of purine nucleoside phosphorylase inhibitors in the treatment of lymphoproliferative disorders of the T-acute lymphoblastic leukemia (ALL) as well as the nonBnonT-ALL subclass.

Topics: Cells, Cultured; Deoxyguanine Nucleotides; Deoxyguanosine; Guanosine; Humans; Leukemia; Lymphocyte Activation; Lymphocytes

Purine nucleoside phosphorylase (NP; EC 2.4.2.1) deficiency is associated with selective T-cell dysfunction and normal B-cell immunity. In order to create an in vivo model of this immune deficiency, we administered 8-aminoguanosine to rats. This water-soluble nucleoside was rapidly converted by NP to the more potent inhibitor 8-aminoguanine, which has a Ki of 0.19 microM. The accumulation of inosine in plasma showed that administration of 8-aminoguanosine was effectively inhibiting NP activity. The administration of 8-aminoguanosine with deoxyguanosine produced increased levels of dGTP only in thymus cells, and increased levels of GTP in cells from thymus, spleen and lymph node and in red cells. This correlated with assays of deoxyguanosine kinase, which showed significantly higher activity in thymus cells than in cells from spleen and lymph node. The intraperitoneal injection of 8-aminoguanosine alone or with deoxyguanosine for 8 consecutive days caused significant decreases in the number of thymus cells (P less than 0.001) and in lymph node and spleen lymphocytes (P less than 0.01). These data showed that the administration of 8-aminoguanosine to rats provided an animal model of NP deficiency that will allow studies of the specific regulation of T-cell function.

Topics: Animals; Deoxyguanine Nucleotides; Deoxyguanosine; Disease Models, Animal; Erythrocytes; Female; Guanosine; Guanosine Triphosphate; Lymphoid Tissue; Male; Pentosyltransferases; Phosphotransferases; Phosphotransferases (Alcohol Group Acceptor); Purine-Nucleoside Phosphorylase; Rats; Rats, Inbred Lew

Topics: B-Lymphocytes; Cell Cycle; Cell Differentiation; Cells, Cultured; Deoxycytidine; Deoxyguanine Nucleotides; Deoxyguanosine; Guanosine; Guanosine Triphosphate; Humans; Hypoxanthine; Hypoxanthine Phosphoribosyltransferase; Hypoxanthines; In Vitro Techniques; Lymphocyte Activation; Purine-Nucleoside Phosphorylase; T-Lymphocytes

Enzyme inhibitors used to simulate the inherited immunodeficiency diseases, adenosine deaminase (ADA) and purine nucleoside phosphorylase (PNP) deficiency, have been assessed in cultured human lymphocytes. Only 2'-deoxycoformycin (dCF) completely inhibited ADA in T and B cells at concentrations in excess of 5 microM. Erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) and 8-amino guanosine (8-NH2GR) did not inhibit ADA or PNP completely at any concentration. Detailed metabolic experiments comparing viability and deoxynucleotide accumulation showed that B cell lines of malignant origin also accumulated high levels of dATP from 2'-deoxyadenosine (dAR), and dGTP from 2'-deoxyguanosine (dGR) as effectively as T cells--even without inhibitors, however, dAR reduced cell viability only when ADA was inhibited by dCF, whilst dGR was equally toxic with or without inhibitor, even to a line which accumulated no dGTP. These experiments indicate that cultured lymphocytes, using either EHNA or 8-NH2GR as enzyme inhibitor, are not valid models of the toxicity to the immune system in inherited ADA or PNP deficiency. They demonstrate that the ability to accumulate high levels of dATP or dGTP is not exclusive to T cells and that the in vitro toxicity of dAR or dGR could relate to the use of excess substrate and/or accumulation in different nucleotide, not deoxynucleotide pools.

Topics: Adenine; Adenosine Deaminase Inhibitors; B-Lymphocytes; Cell Line; Cell Survival; Coformycin; Deoxyadenine Nucleotides; Deoxyadenosines; Deoxyguanine Nucleotides; Deoxyguanosine; Dose-Response Relationship, Drug; Guanosine; Humans; Pentostatin; Purine-Nucleoside Phosphorylase; T-Lymphocytes